Zicronapine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Zicronapine
Zicronapine.svg
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C22H27ClN2
Molar mass 354.9 g/mol
3D model (JSmol)

Zicronapine (/zˈkrɒnəpn/ zye-KRON-ə-peen, previously known as Lu 31-130) is an atypical antipsychotic medication formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.[1]

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.[2]

In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising medicine Lu AF35700.[3] i.e. Elopiprazole?

References[edit]